|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.34 HKD | -1.47% |
|
+4.69% | -8.22% |
| Apr. 03 | Ascletis Discontinues Trials of FXR Agonist for Biliary Cholangitis, NASH and Hepatitis B Virus | MT |
| Apr. 03 | Ascletis Pharma Inc. Announces Strategic Decisions on FXR Agonist ASC42 | CI |
Ascletis Pharma Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was CNY 56.6 million compared to CNY 54.09 million a year ago. Net loss was CNY 144.72 million compared to CNY 314.84 million a year ago.
Basic loss per share from continuing operations was CNY 0.1347 compared to CNY 0.2896 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -8.22% | 173M | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| -9.14% | 11.95B | |
| +5.24% | 8.71B | |
| -8.42% | 8.12B |
ASCLETIS PHARMA INC. 
